Displaying 641 - 660 of 1552
FTC Returns Money to Consumers Tricked into Buying Phony Health Insurance
FTC Posts Agenda for September 21 Workshop to Examine Advertising for Over-the-Counter Homeopathic Products
Zimmer Holdings, Inc. / Biomet, Inc., In the Matter of
Medical device company Zimmer Holdings, Inc. agreed to divest U.S. rights and assets related to unicondylar knee implants, total elbow implants, and bone cement in order to settle FTC charges that its proposed $13.35 billion acquisition of Biomet Inc. is anticompetitive. According to the complaint, Zimmer and Biomet are two of the only three substantial competitors in the U.S. markets for unicondylar knee implants and total elbow implants, and two of only four significant competitors in the U.S. market for bone cement. The order requires Zimmer to divest to Smith & Nephew the U.S. intellectual property, manufacturing technology, and existing inventory relating to its unicondylar knee implant, and to provide transitional services to help them establish manufacturing capabilities and secure necessary FDA approvals. The order also requires Biomet to divest to DJO the U.S. intellectual property, manufacturing technology, and existing inventory relating to its total elbow implant and bone cement products, and it facilitates DJO’s hiring of the Biomet sales representatives and other staff who work with these products.
Statement of Chairwoman Edith Ramirez In the Matter of LabMD, Inc.
FTC Action: Scammers Banned from Selling Healthcare Products
FTC Staff Comment, and Concurring Comment of Commissioner Wright, Regarding North Carolina House Bill 200, Which Would Exempt Diagnostic Centers, Ambulatory Surgical Facilities and Psychiatric Hospitals From Certificate of Need Regulation
FTC Staff Supports North Carolina Legislative Proposal to Limit Certificate of Need Rules for Health Care Facilities
Plymouth Direct, Inc. (BeActive Brace)
FTC Staff Urges Minnesota Legislature to Weigh Benefits and Risks of Disclosing Terms of State Health Care Services Contracts
Statement of Chairwoman Edith Ramirez - In the Matter of LabMD, Inc.
PhRMA a/k/a Pharmaceutical Research and Manufacturers of America
FTC Staff Urges New York Legislature to Reconsider Proposed Legislation to Grant Antitrust Immunity to Certain Health Care Collaborations
FTC Staff Comment to New York State Senator Ranzenhofer and New York State Assemblyman Abinanti Concerning SB 2647 and AB 2888 Authorizing Certain Agreements for the Creation and Operation of a Health Care Delivery System Network
Keynote Remarks of FTC Chairwoman Edith Ramirez
Opening Remarks by FTC Chairwoman Edith Ramirez at Cephalon/Teva Settlement Press Conference
Separate Statement of Commissioners Maureen K. Ohlhausen and Joshua D. Wright Federal Trade Commission v. Cephalon, Inc.
Statement of the Federal Trade Commission FTC v. Cephalon, Inc.
Displaying 641 - 660 of 1552